VRF Eye Specialty Group

1. AbbVie, Inc. $383,027 42 payments
2. Sun Pharmaceutical Industries Inc. $19,100 11 payments
3. Allergan Inc. $14,365 1 payment
4. Novartis Pharmaceuticals Corporation $2,503 4 payments

1. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $251,237 30 payments
2. AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $68,709 5 payments
3. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $25,865 2 payments
4. SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $18,250 1 payment
5. A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis $14,806 6 payments
6. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $14,521 2 payments
7. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $14,365 1 payment
8. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $2,782 1 payment
9. A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery $2,320 3 payments
10. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $2,268 2 payments

1. Other $17,125 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.